Pfizer Inc (NYSE: PFE) To Acquire Global Blood Therapeutics For $5 Billion

According to sources familiar with the matter, the Wall Street Journal reported that Pfizer Inc (NYSE: PFE) was in advanced discussions to acquire pharmaceutical company Global Blood Therapeutics (NASDAQ: GBT) for $5 billion. Pfizer, too, acquired Global Blood Therapeutics  Pfizer wants to close a deal soon, but there are still other interested parties, according to […]

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) Receives Regulatory Approval For COVID-19 Vaccine in Younger Teenagers

Pfizer Inc (NYSE: PFE) and BioNTech SE received full regulatory authorization for their COVID-19 Vaccine for adolescents between 12 and 15 years in the US, which is a major milestone that will enable the drug manufacturers to continue marketing the vaccines to teenagers after the pandemic. Pfizer’s COVID-19 vaccine approved for teens between 12-15 years […]

Big Pharma Deals: Pfizer Inc. (NYSE: PFE) Partners with Valneva SE in the Fight against Lyme Disease

One of the big pharma entities in the U.S., Pfizer Inc. (NYSE: PFE), just got into a deal with French jab manufacturer Valneva SE. The timing of this deal couldn’t have come at a better time, given the setback and reputational risks that Valneva has been facing in its Covid-19 vaccine candidate disagreement with the […]

Pfizer Inc. (NYSE: PFE) Has Developed a COVID-19 Vaccine For Children Under 5

Pfizer Inc. (NYSE: PFE) is continuing to make efforts toward protecting young children from COVID-19 infection. The company has recently announced that three shots of its vaccines could offer ample protection for those under five. Pfizer intends to submit its results to regulators. Modern Inc (NASDAQ: MRNA) has developed a vaccine for children under five […]

Pfizer Inc. (NYSE: PFE) Is About to Trade Ex-dividend

Pfizer Inc. (NYSE: PFE) has announced that it will soon trade ex-dividend. This announcement signals the company’s investors to make their moves. The ex-dividend date refers to the day before a company decides which of its shareholders will get a dividend. Pfizer’s dividend will be $0.40 per share. Pfizer announces the real-world benefits of IBRANCE […]

Pfizer Inc. (NYSE: PFE) Finds That Paxlovid Cannot Prevent COVID-19 Infection

Pfizer Inc. (NYSE: PFE) has found that its Paxlovid pill might not effectively prevent COVID-19 in people who have come in contact with infected individuals. Paxlovid is an oral drug which the Food and Drug Administration (FDA) approved for the treatment of COVID-19. In the study, the company gave the pill to people for five […]

Pfizer Inc. (NYSE: PFE) Has Produced 6 Million Paxlovid Pills

Pfizer Inc. (NYSE: PFE) announced that it surpassed the target that Albert Bourla, its CEO, set and developed 6 million Paxlovid pills. Paxlovid is an oral pill that treats COVID-19. The company also stated that it had sent these pills to 26 counties. It hopes to create about 120 million pills in 2022. Meanwhile, the […]

Pfizer Inc. (NYSE: PFE) Gets Breakthrough Therapy Designation For RSVpreF

The U.S Food and Drug Administration (FDA) has given Pfizer Inc. (NYSE: PFE) the Breakthrough Designation for RSVpreF, its vaccine for respiratory syncytial virus (RSV). The vaccine is for people aged 60 and above. This move comes after Pfizer conducted a Phase IIa clinical trial that looked into the efficacy, immunogenicity, and safety of the […]

Pfizer Inc. (NYSE: PFE) Study Shows The Company Gives Equitable Pay to Workers

Pfizer Inc. (NYSE: PFE) has stated for the third time that a compensation expert has recognized that the company offers equitable pay to workers. This announcement came after a study on gender-based pay worldwide and for U.S minorities. It used bonuses, merit increases, and base pay to assess payment equity. The study also adjusted for […]

Pfizer Inc. (NYSE: PFE) Drug, Paxlovid, Becomes Readily Available As Omicron Subsides

The Pfizer Inc. (NYSE: PFE) drug, Paxlovid, is becoming more available as the number of omicron infections dwindles. The drug which the Food and Drug Administration (FDA) approved had been difficult to obtain during the spike, leaving a gap for patients with mild cases of the disease. Meanwhile, Pfizer and BioNTech SE’s (NASDAQ: BNTX) omicron […]

Pfizer Inc. (NYSE: PFE) and Other Biotechnology Service Companies Could Reach a Market Capitalization of $151.10 Billion

Pfizer Inc. (NYSE: PFE) is among the companies in the biotechnology services market that analysts expect to grow in 2022. These companies could amass a market cap of $151.10 billion in 2022. Other significant players in this category include Precision for Medicine, BioAlps, Novo Nordisk, Pfizer, Fisher BioService, and Novartis. The FDA and CDC are […]

Pfizer Inc. (NYSE: PFE) Records a Gain of 42.2% in the Last Six Months

Pfizer Inc. (NYSE: PFE) has gained 42.2% in the past six months. This is because of some of its breakthrough projects, including receiving approval from the Food and Drug Administration (FDA) for its COVID-19 booster. The company also received approval for vaccines for children between 12 to 15. Moreover, Pfizer received Breakthrough Therapy Designation (“BTD”) […]

Pfizer Inks A Research Collaboration with Beam Therapeutics

Pfizer (PFE) has inked four-year research collaboration agreement with biotechnology company Beam Therapeutics (BEAM). The two are joining forces to advance the development of novel in-vivo base editing programs. PFE shares rose 0.93% to close at $56.24 on January 10. Pfizer is a company that develops, manufactures, and distributes healthcare products, including medicine and vaccines. […]

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) Are Partnering on a Shingles mRNA Vaccine

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have begun a new partnership to commercialize, develop, and research an mRNA vaccine for Shingles.  The disease, a form of the varicella-zoster virus, affects about 1 in 3 Americans. It affects people with cancer and those above the age of 50. It causes painful, disfiguring patches. […]

Pfizer Inc. (NYSE: PFE) Releases More Data on Its Oral Drug for COVID-19

Pfizer Inc. (NYSE: PFE) has released additional data from the clinical trial of its oral COVID-19 drug. The company found that Paxlovid, the antiviral, was 89% efficient in protecting high-risk populations from dying or hospitalization due to COVID-19. The total dose consists of three pills taken two times a day for five days. It prevents […]